“This is an important partnership that could lead to significant breakthroughs in the way critically ill patients in the Middle East are treated,” said Dr. Abdulla Ibrahim Al Khayat, CEO of the Specialty Children’s Hospital. AlJalila.
“The agreement demonstrates our intention to work with the best in the genome industry and leverage cutting-edge technologies to help these genetically underrepresented patients and their families across the region.
The study, which will begin before the end of 2022, will see Illumina – an American biotechnology company founded in 1998 and headquartered in California – support the study by providing sequencing reagents and analytical tools for the rapid sequencing of whole genome.
The study will include 200 children under the age of 18, including infants, as well as parents (for the segregation analysis). All will be tested over a 24-month period and half of the patients are expected to be Emirati.
Dr Ahmad Abou Tayoun, principal investigator leading the study at Al Jalila Children’s, said: “The results are primarily aimed at determining the impact of rapid whole genome sequencing results on clinical diagnosis and management. of patients, including their length of stay. , changes in care or treatment, additional procedures, and the elimination of additional diagnostic workloads. A secondary objective includes assessing the cost impact of the rWGS – for example, whether it leads to shorter hospital stays and the elimination of certain diagnostic or management workloads.
The Al Jalila Children’s Genome Center has received CAP accreditation, a recognition that certifies that its laboratory operates to the highest standards of quality, accuracy and consistency. The state-of-the-art center offers genomic testing and counseling for children and adults. With its diagnostic laboratory and a fully equipped clinic, in addition to a team of certified precision medicine experts, the center provides the regional community with specialized genetic counseling to support patients, families and other physicians.
“We are delighted to be working with Al Jalila Children’s Specialty Hospital to show the value of rapid whole genome sequencing in speeding up the time to definitive diagnosis for critically ill children with suspected genetic disease and improving outcomes for patients,” said Susan Tousi, Illumina Chief Commercial Officer.
“We are committed to increasing genomics capabilities in the UAE – our recently opened Dubai Solutions Center houses the latest sequencing technologies to provide even more support to our customers in the region, helping them deliver genomic precision medicine to a growing number of patients.